Search clinical trials for: BAY86-6150

Total 1182 results

Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Bayer

Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Contrast Enhanced X-ray Based Examination

Germany
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Bayer

Completed

Japanese BAY86-9766 Monotherapy Phase I Study

Neoplasms

Japan
Bayer
Titan Pharmaceuticals

Terminated

Pilot Study of Safety and Efficacy of Spheramine

Parkinson''s Disease

United States
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer
Titan Pharmaceuticals

Terminated

STEPS Trial - Spheramine Safety and Efficacy Study

Parkinson Disease

Spain, United States, Germany
Bayer
TAP Pharmaceutical Products Inc.

Completed

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

Menorrhagia
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan
Bayer

Completed

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Magnetic Resonance Imaging

Philippines
Bayer

Completed

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Hypersensitivity

Germany
Bayer

Completed

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Magnetic Resonance Imaging

United States, Canada, Germany
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Bayer

Completed

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination (IMAGE)

Diagnostic Imaging

Poland, China, Germany, Hungary, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, Thailand, Philippines, Taiwan, Italy, Moldova, Republic of, Romania, Russian Federation, Ukraine, Bosnia and Herzegovina, Pak... and more
ELA Medical, Inc.

Completed

Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study (Post-Ovatio)

Sudden Cardiac Death

United States
Bayer

Completed

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

Carotid Stenosis

France, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
Bayer

Completed

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Magnetic Resonance Imaging | Magnetic Resonance Angiography

Poland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
Bayer

Completed

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Epidemiologic Factors

Germany
Bayer

Completed

Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea

Contraception

Korea, Republic of
Bayer

Completed

Julina Post-marketing Surveillance for Climacteric Symptoms in Japan (JULINA-CLIMA)

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Fibrosis | Renal Insufficiency | Kidney Failure

United States
Bayer

Completed

Myocardial Perfusion MRI

Magnetic Resonance Imaging | Myocardial Perfusion Imaging

Switzerland, Germany, Austria, Poland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases

Korea, Republic of, United States, Colombia, China, Argentina
Bayer

Completed

Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease

Peripheral Vascular Diseases

Germany, Switzerland, Argentina, Austria, Mexico, Brazil
Bayer
Navitas Life Sciences GmbH; LKF Laboratory

Completed

Efficacy of Gynodian® Depot in Women With Impaired Well-being

Hormone Replacement Therapy
Bayer

Completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Completed

Drug Use Investigation of Gadovist.

Magnetic Resonance Imaging | Image Enhancement

Japan
Bayer

Completed

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Myocardial Infarction

United States, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) (GEMMA 2)

Breast Cancer

Spain, Canada, Taiwan, United States, India, Netherlands, Poland, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Bayer

Completed

Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

Endometriosis

Italy, Germany, Ukraine
Bayer

Completed

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 2)

Coronary Artery Disease

United States, Canada, Singapore, Australia
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

Contrast-enhanced MRI in Children 2 Months to <2 Years

Magnetic Resonance Imaging

United States, Germany
Bayer

Completed

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Magnetic Resonance Imaging

Sweden, Canada, Austria, Germany
Bayer

Completed

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Peripheral Vascular Disease
Bayer

Completed

Magnevist Post-marketing Surveillance in Japan

Diagnostic Imaging

Japan
Andarix Pharmaceuticals

Recruiting

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Small Cell | Neoplasm Recurrence, Local

United States
Bayer

Completed

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Brain Metastases

Japan
Bayer

Completed

Primovist Post-marketing Surveillance in Japan (PRIMOVIST)

Diagnostic Imaging

Japan
Bayer

Completed

Primovist / Eovist in Renally Impaired Patients (PERI)

Contrast Media

United States, Germany, Italy, Korea, Republic of, Austria, Thailand, Australia, Spain, United Kingdom
Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Bayer

Completed

Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain

Endometriosis

Spain, Sweden, France, Finland, Denmark, Netherlands, Czech Republic
Bayer

Completed

Efficacy and Safety of SH T00660AA in Treatment of Endometriosis

Endometriosis
Bayer

Completed

Wellnara Post-marketing Surveillance in Japan (WELLNARA)

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Central Nervous System Diseases

China

Search clinical trials for: BAY86-6150

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations